Narrow search
Showing 1 - 10 of 36,511
Cover Image
Treating Allergic Asthma with Omalizumab
Belliveau, Paul P.; Lahoz, Monina R. - In: Disease Management and Health Outcomes 15 (2007) 3, pp. 165-179
Asthma is a chronic condition with characteristics that make it an ideal target for interventions used within disease state management in managed care settings. It affects a substantial population of patients and imposes an increasingly significant global societal burden. Despite the...
Persistent link: https://www.econbiz.de/10005243038
Cover Image
Health Economics in the Canadian Pharmaceutical Industry
Assiff, Lila; Pollock, Michael R.; Manzi, Patricia; … - In: PharmacoEconomics 16 (1999) 6, pp. 669-678
companies have evolved from supporting efforts to gain reimbursement on government drug plans to include pricing, promotion …
Persistent link: https://www.econbiz.de/10005243179
Cover Image
Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands
Hoomans, Ties; Severens, Johan L.; van der Roer, Nicole; … - In: PharmacoEconomics 30 (2012) 3, pp. 219-227
Background:Background: In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost … evidence and the decision-making process about drug reimbursement. Abstract: Aim:Aim: This study reviewed the methodological … Health Care Insurance Board (CVZ). The Board's newsletters provided information on the advice to, and reimbursement decisions …
Persistent link: https://www.econbiz.de/10009493384
Cover Image
Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia: South Korea, Taiwan, Thailand and Japan
Kamae, Isao - In: PharmacoEconomics 28 (2010) 10, pp. 831-838
Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st...
Persistent link: https://www.econbiz.de/10008519880
Cover Image
Actual Costs Versus Diagnostic-Related Group Reimbursements for Unstable Angina: An Important Distinction for Effective Disease Management
Brunelli, Claudio; Bezante, Gian Paolo; Pasdera, Alberto; … - In: Disease Management and Health Outcomes 5 (1999) 4, pp. 225-232
regarding diagnostic and therapeutic procedures for these patients compared with the reimbursement rates established by the … to gather all the information necessary to establish whether reimbursement rates are covering real costs and to initiate …
Persistent link: https://www.econbiz.de/10005448793
Cover Image
On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data: Concepts of Income-Based Deductibles and Issues Related to Causal Inference
Schneeweiss, Sebastian; Maclure, Malcolm; Dormuth, Colin - In: Disease Management and Health Outcomes 10 (2002) 12, pp. 763-769
Cost containment in pharmaceutical benefits plans is often controversial because of its potential for unintended effects on health and overall expenditures. Thorough evaluations are needed to support benefits plans in developing evidence-based policies. Evaluations of income-based deductibles...
Persistent link: https://www.econbiz.de/10005448815
Cover Image
The Pros and Cons of Covering Lifestyle Drugs
Reissman, Debi - In: Disease Management and Health Outcomes 6 (1999) 5, pp. 249-251
The purchase of `lifestyle' enhancing therapies by purchasers such as patients and insurers is projected by some to double the level of US spending on pharmaceuticals over the coming 5 to 10 years. Health plans struggling with the balance between the ability to increase medical premiums and the...
Persistent link: https://www.econbiz.de/10005448872
Cover Image
Medical Savings Account Plans: A Patient-Centred Approach to Medical Insurance
Springer, David T. - In: Disease Management and Health Outcomes 8 (2000) 1, pp. 9-15
Medical savings account (MSA) plans are a form of medical insurance that combine high-deductible medical insurance with a tax-free personal trust account (used to pay medical bills not covered by insurance). MSA-like plans have been in existence in US companies for over 10 years, in Singapore...
Persistent link: https://www.econbiz.de/10005448925
Cover Image
Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors
van de Putte, Leo; Nichol, Michael B. - In: Disease Management and Health Outcomes 12 (2004) 1, pp. 1-8
over the long run. TNF antagonists can be valuable for patients in need and therefore appropriate for reimbursement by …
Persistent link: https://www.econbiz.de/10005448938
Cover Image
Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada
Morgan, Steve; McMahon, Meghan; Mitton, Craig - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 67-73
Drug coverage decisions require information about clinically relevant benefits and risks, as well as economic information about direct and indirect costs, in comparison with relevant treatment alternatives. A recent Canadian initiative aims to improve the evidentiary basis for drug coverage...
Persistent link: https://www.econbiz.de/10005448962